Novo Nordisk's Pipeline Progress Collides With a Fast-Moving Rival in China

Novo Nordisk secured European approval on Friday for its haemophilia A therapy FREHEMGO, a regulatory green light that helped lift the shares 2.7% on the day, according to Reuters. Yet the same week brought a reminder that medical wins do not translate automatically into commercial advantage: Eli Lilly won Chinese approval on Thursday for its oral GLP-1 weight-loss pill Orforglipron, making it the first drugmaker to clear that bar in the country and handing it a lead over its Danish rival.

The juxtaposition frames the central question facing investors. Can a steady stream of product milestones outweigh intensifying competition and lingering safety questions? The European approval strengthens that case without settling it.

A charitable pledge and a raised forecast set the backdrop

Away from the regulatory headlines, Novo Nordisk committed USD 200 million on Wednesday to the World Diabetes Foundation, funding that will support diabetes prevention and care in low- and middle-income countries over the 2027–2036 period. The pledge covers both efforts to head off the disease and treatment for those already living with it.

The company's financial guidance has also moved in a more constructive direction. In its November 4 update, Novo Nordisk raised its full-year outlook and said it expects adjusted sales and adjusted operating profit for 2026 to develop between -2% and +2% at constant currencies. Third-quarter 2026 adjusted operating profit climbed 27% at constant exchange rates to DKK 31.7 billion, according to the company's mandatory disclosure.

FREHEMGO clears Brussels, with a launch to follow

The European Commission's approval of FREHEMGO, whose active ingredient is denecimig, covers routine prevention of bleeding episodes in adults and children with haemophilia A, with or without inhibitors. Novo Nordisk plans its first European launches in the coming year and says the drug allows for weekly, fortnightly or monthly dosing.

That decision is a completed regulatory step, not a revenue line. The bull case requires the approval to be converted into commercially meaningful business; investors would do well to treat the green light as a precondition rather than proof of any particular sales contribution.

Sickle cell filing puts 2027 in the diary

The same principle applies across the pipeline, where clinical results, submitted applications and granted approvals sit at very different stages. Conflating them would mean valuing future possibilities as if they were already banked.

Novo Nordisk filed Etavopivat with the US Food and Drug Administration and the European Medicines Agency on Friday, seeking approval of the once-daily investigational treatment for sickle cell disease in adolescents and adults. The submissions rest on data from the Phase 3 HIBISCUS trial, and the company expects regulatory decisions in 2027. A Phase 3 study previously showed a 27% reduction in vaso-occlusive crises versus placebo, according to the company.

CagriSema data come with an important caveat

Results from the Phase 3 REDEFINE 9 trial for CagriSema, presented at ObesityWeek and published in The Lancet Diabetes & Endocrinology, offer further support for the pipeline's potential. The two lower doses produced estimated average weight losses of 20.7% and 21.0%, per the company — but only among participants who continued treatment. That condition matters: the figures describe an outcome under that assumption and should not be read as an unconditional expectation of effect.

Competition and safety labels temper the optimism

The bear case starts with the competitive picture. Lilly's Chinese approval gives it a head start in that market, creating a risk that Novo Nordisk's own clinical advances will not automatically convert into an equally strong commercial position.

Drug safety adds a second layer. Reuters reported on November 9 that the FDA requested additional information in the prescribing information for GLP-1 medicines, including Novo Nordisk's Ozempic and Wegovy. The addition concerns a potentially increased risk of non-arteritic anterior ischaemic optic neuropathy. The requirement deserves the same attention as positive trial news, though it addresses a potential risk and does not support blanket conclusions about all treatments.

What to watch between now and 2027

As long as Novo Nordisk can turn its medical progress into further approvals and commercially relevant products, the optimistic case holds together. Should competitive and safety concerns instead weigh more heavily on that conversion, single approval wins may prove too thin to support a more favourable valuation.

The next explicitly flagged regulatory waypoint is the expected 2027 decisions on Etavopivat. Until then, the investor's task is to keep progress and execution apart: FREHEMGO holds a European approval, Etavopivat sits in the filing stage, and CagriSema remains investigational. How strong the outlook proves depends on which of these opportunities reaches its next stage.